Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis

Til Menge, Divyanshu Dubey, Clemens Warnke, Hans Peter Hartung, Olaf Stüve

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Despite recent advances in pharmacological management, multiple sclerosis (MS), an autoimmune disease of the central nervous system, remains a leading cause of disability. In relapsing-remitting (RR)MS, neurologists most commonly utilize immunomodulatory or immunosuppressive agents to benefit their patients. With the introduction of humanized monoclonal antibodies (mAbs) ablation of distinct immune populations has become possible. Depletion of B cells by anti-CD20 mAbs has repeatedly proven to be a very rapid and effective means to diminish disease activity in RRMS. Areas covered: We discuss the biological rationale, development, and recent clinical study results of the second generation anti-CD20 mAb ocrelizumab. Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. The short term adverse events profile appears favorable. However, long-term effects of repeated B cell depletion are currently unknown.

Original languageEnglish (US)
Pages (from-to)1131-1139
Number of pages9
JournalExpert Review of Neurotherapeutics
Volume16
Issue number10
DOIs
StatePublished - Oct 2 2016

Fingerprint

ocrelizumab
Relapsing-Remitting Multiple Sclerosis
B-Lymphocytes
Autoimmune Diseases of the Nervous System
Antibodies, Monoclonal, Humanized
Phase III Clinical Trials
Interferon-beta
Immunosuppressive Agents
Multiple Sclerosis
Central Nervous System
Randomized Controlled Trials
Monoclonal Antibodies
Pharmacology
Therapeutics
Population

Keywords

  • autoimmunity
  • B cells
  • B lymphocytes
  • CD19
  • CD20
  • EAE
  • experimental autoimmune encephalomyelitis
  • MS
  • multiple sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. / Menge, Til; Dubey, Divyanshu; Warnke, Clemens; Hartung, Hans Peter; Stüve, Olaf.

In: Expert Review of Neurotherapeutics, Vol. 16, No. 10, 02.10.2016, p. 1131-1139.

Research output: Contribution to journalArticle

Menge, Til ; Dubey, Divyanshu ; Warnke, Clemens ; Hartung, Hans Peter ; Stüve, Olaf. / Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. In: Expert Review of Neurotherapeutics. 2016 ; Vol. 16, No. 10. pp. 1131-1139.
@article{f95c567d165e4e52aa4062ec321d6584,
title = "Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis",
abstract = "Introduction: Despite recent advances in pharmacological management, multiple sclerosis (MS), an autoimmune disease of the central nervous system, remains a leading cause of disability. In relapsing-remitting (RR)MS, neurologists most commonly utilize immunomodulatory or immunosuppressive agents to benefit their patients. With the introduction of humanized monoclonal antibodies (mAbs) ablation of distinct immune populations has become possible. Depletion of B cells by anti-CD20 mAbs has repeatedly proven to be a very rapid and effective means to diminish disease activity in RRMS. Areas covered: We discuss the biological rationale, development, and recent clinical study results of the second generation anti-CD20 mAb ocrelizumab. Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. The short term adverse events profile appears favorable. However, long-term effects of repeated B cell depletion are currently unknown.",
keywords = "autoimmunity, B cells, B lymphocytes, CD19, CD20, EAE, experimental autoimmune encephalomyelitis, MS, multiple sclerosis",
author = "Til Menge and Divyanshu Dubey and Clemens Warnke and Hartung, {Hans Peter} and Olaf St{\"u}ve",
year = "2016",
month = "10",
day = "2",
doi = "10.1080/14737175.2016.1227242",
language = "English (US)",
volume = "16",
pages = "1131--1139",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis

AU - Menge, Til

AU - Dubey, Divyanshu

AU - Warnke, Clemens

AU - Hartung, Hans Peter

AU - Stüve, Olaf

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Introduction: Despite recent advances in pharmacological management, multiple sclerosis (MS), an autoimmune disease of the central nervous system, remains a leading cause of disability. In relapsing-remitting (RR)MS, neurologists most commonly utilize immunomodulatory or immunosuppressive agents to benefit their patients. With the introduction of humanized monoclonal antibodies (mAbs) ablation of distinct immune populations has become possible. Depletion of B cells by anti-CD20 mAbs has repeatedly proven to be a very rapid and effective means to diminish disease activity in RRMS. Areas covered: We discuss the biological rationale, development, and recent clinical study results of the second generation anti-CD20 mAb ocrelizumab. Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. The short term adverse events profile appears favorable. However, long-term effects of repeated B cell depletion are currently unknown.

AB - Introduction: Despite recent advances in pharmacological management, multiple sclerosis (MS), an autoimmune disease of the central nervous system, remains a leading cause of disability. In relapsing-remitting (RR)MS, neurologists most commonly utilize immunomodulatory or immunosuppressive agents to benefit their patients. With the introduction of humanized monoclonal antibodies (mAbs) ablation of distinct immune populations has become possible. Depletion of B cells by anti-CD20 mAbs has repeatedly proven to be a very rapid and effective means to diminish disease activity in RRMS. Areas covered: We discuss the biological rationale, development, and recent clinical study results of the second generation anti-CD20 mAb ocrelizumab. Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. The short term adverse events profile appears favorable. However, long-term effects of repeated B cell depletion are currently unknown.

KW - autoimmunity

KW - B cells

KW - B lymphocytes

KW - CD19

KW - CD20

KW - EAE

KW - experimental autoimmune encephalomyelitis

KW - MS

KW - multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84984683794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984683794&partnerID=8YFLogxK

U2 - 10.1080/14737175.2016.1227242

DO - 10.1080/14737175.2016.1227242

M3 - Article

C2 - 27552111

AN - SCOPUS:84984683794

VL - 16

SP - 1131

EP - 1139

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 10

ER -